Related Experiment Video

Updated: Jul 14, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Concomitant Hypertension in Hypertrophic Cardiomyopathy: Clinical Phenotype and Prognostic Associations of

Jeremy Florence1,2,3,4,5, Trecy Gonçalves1,2,3,4,6, Solenn Toupin1,2,3

  • 1Université Paris Cité, Department of Cardiology, University Hospital of Lariboisiere, (Assistance Publique des Hôpitaux de Paris, AP-HP), 75010, Paris, France.

European Journal of Preventive Cardiology
|July 13, 2026
PubMed

Insights

Hypertension in hypertrophic cardiomyopathy (HCM) patients increases mortality risk. Cardiovascular magnetic resonance (CMR) biomarkers like late gadolinium enhancement (LGE) predict outcomes in both hypertensive and non-hypertensive HCM individuals.

Area of Science:

  • Cardiology
  • Cardiovascular Imaging
  • Genetics and Genomics

Background:

  • Hypertrophic cardiomyopathy (HCM) is a primary genetic heart muscle disease.
  • Hypertension is a common comorbidity in HCM patients.
  • The prognostic impact of hypertension on HCM outcomes requires further investigation.

Purpose of the Study:

  • To define the cardiovascular magnetic resonance (CMR) characteristics of hypertensive HCM patients.
  • To evaluate the association between hypertension and all-cause mortality in HCM.
  • To compare the prognostic value of CMR biomarkers in hypertensive versus non-hypertensive HCM patients.

Main Methods:

  • A multicenter registry (HCM-LGE) included 2,873 HCM patients (2008-2024).
  • Cardiovascular magnetic resonance (CMR) assessed cardiac structure, function, and late gadolinium enhancement (LGE).
  • Survival analysis evaluated the prognostic impact of hypertension and CMR biomarkers.

Main Results:

  • 28% of HCM patients had hypertension, exhibiting greater LGE extent, more LGE locations, and more midwall LGE.
  • Hypertensive HCM patients had a significantly increased risk of all-cause mortality (HR: 1.32; p=0.024) after propensity score matching.
  • High LGE extent (>3 segments) and septal LGE location independently predicted mortality in both hypertensive and non-hypertensive HCM groups.

Conclusions:

  • Concomitant hypertension is linked to increased long-term mortality in a large HCM cohort.
  • CMR-derived LGE biomarkers retain prognostic significance in hypertensive HCM patients.
  • Comprehensive cardiovascular risk assessment is crucial for managing HCM patients, especially those with hypertension.
Abstract

Keywords:
all-cause mortalitycardiovascular magnetic resonancehypertensionhypertrophic cardiomyopathylate gadolinium enhancement

More Related Videos

Quantification of Mouse Heart Left Ventricular Function, Myocardial Strain, and Hemodynamic Forces by Cardiovascular Magnetic Resonance Imaging11:13

Quantification of Mouse Heart Left Ventricular Function, Myocardial Strain, and Hemodynamic Forces by Cardiovascular Magnetic Resonance Imaging

Published on: May 24, 2021

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Mitral Regurgitation II: Clinical Features and Diagnostic Tests01:23

Mitral Regurgitation II: Clinical Features and Diagnostic Tests

Mitral regurgitation (MR) is a valvular heart disorder in which the mitral valve fails to close tightly, allowing blood to leak backward into the heart. Understanding the clinical manifestations, assessment, diagnostic findings, and medical management of MR is crucial to effectively managing affected patients.Clinical Manifestations of Mitral RegurgitationMitral regurgitation can be acute or chronic, each presenting differently and requiring different approaches:1. Acute Mitral...